Key points are not available for this paper at this time.
No takes yet. Share an insight, caveat, or question.
Nebivolol was associated with fewer ischaemic events in elderly ischaemic HF; extends β-blocker benefit beyond HF outcomes but needs prospective confirmation.
Ambrosio et al. (2010) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: